Affiliation:
1. Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis The First Affiliated Hospital of Soochow University Suzhou China
2. Collaborative Innovation Center of Hematology Soochow University Suzhou China
Abstract
AbstractMyeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations who was treated with the combination of the second‐generation TKI nilotinib and JAK1/JAK2 inhibitor ruxolitinib.
Funder
China Postdoctoral Science Foundation
National Key Research and Development Program of China
National Science and Technology Major Project
National Natural Science Foundation of China
Natural Science Foundation of Jiangsu Province
Government of Jiangsu Province
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献